Weekly versus monthly drug regimens: 1-Year compliance and persistence with bisphosphonate therapy

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1831-1839

  Gold, Deborah T ^a   Trinh, Haian ^b   Safi, Wael ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Adherence; Bisphosphonates; Compliance; Ibandronate; Osteoporosis; Persistence; Risedronate

Indexed keywords

IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG MARKETING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRESCRIPTION; TREATMENT RESPONSE;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG PRESCRIPTIONS; ETIDRONIC ACID; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 67650799140     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903035604     Document Type: Article

References (50)

1. World Health Organization. Osteoporosis: both health organizations and individuals must act now to avoid an impending epidemic. Press release WHO/58 11 October 1999. Available at: www.who.int/inf-pr-1999/en/pr99-58.html [Last accessed 16 November 2006]
2. National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008
3. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
5. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
6. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
7. Chesnut 3rd CH, Skag A, Christiansen C, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
8. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
9. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
10. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
11. Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
12. Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757-64
13. Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003;14:437-41
14. Delmas PD, Recker RR, Chesnut 3rd CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8
15. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4 Suppl 1):S12-17
16. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
17. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
18. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001;10:42-5
19. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
20. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
21. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
22. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
23. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
24. van Staa TP, Leufkens HGM, Cooper C. Is persistence to bisphosphonate therapy related only to dosing regimen? Osteoporos Int 2006;17(Suppl 1):S77
25. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61
26. Rossini M, Bianchi G, Di Munno O, et al. Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
27. Van Staa TP, Geusens P, Leufkens HGM, et al. Persistence to bisphosphonate treatment in actual clinical practice. European Calcified Tissue Society meeting, June 25-29, 2005, Geneva, Switzerland [abstract P610-Su].
28. Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905.
29. Weiss TW, Henderson SC, McHorney CA, et al. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007;23:2193-203
30. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91
31. Weiss TW, von Allmen H, Henderson SC, et al. Persistency rates across weekly and monthly bisphosphonates: results from the IMS health longitudinal prescription database. J Bone Miner Res 2006;21(Suppl 1):S419
32. IMS Longitudinal Prescription database from IMS Health. Accessed May 2006.
33. Akesson K, Beusterien K, Hebborn A, et al. Strong patient preference for once-monthly over weekly oral bisphosphonate dosing in postmenopausal osteoporosis. Osteoporos Int 2005;16(Suppl 4): [abstract P622-Su]
34. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
35. Benhamou C, Licata AA, Devas V, et al. Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis: the BALTO II study. European Calcified Tissue Society meeting, May 10-14, 2006, Prague, Czech Republic [abstract P350].
36. Weiss TW, Gold DT, Silverman SL, et al. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 2006;22:949-60
37. Walliser JA, Bolge SC, Sen SS. Patients' preference for osteoporosis medications: PREFER-International. International Society for Clinical Densitometry meeting, February 1-4, 2006, San Diego, CA, USA: [abstract 213].
38. Walliser J, Bolge S, Sen SS. Patients' perception of importance of different attributes of osteoporosis medication: results from the PREFER-International study. European Calcified Tissue Society meeting, May 10-14, 2006, Prague, Czech Republic: [abstract P464].
39. Keen R, Jodar E, Iolascon G, et al. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 2006;22:2375-81
40. Koay MA, Walker M, Corner A, et al. Improved patient education and support may enhance adherence to bisphosphonate therapy. European Calcified Tissue Society meeting, May 10-14, 2006, Prague, Czech Republic: [abstract P480].
41. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
42. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9
43. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35
44. Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-8
45. International Society for Pharmacoeconomics and Outcomes Research. ISPOR Medication Compliance and Persistence Special Interest Group: Accomplishments. Available at: www.ispor.org/sigs/MCP-accomplishments.asp [Last accessed May 21, 2007].
46. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
47. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34
48. Ayanian JZ. Using administrative data to assess health care outcomes. Eur Heart J 1999;20:1689-91
49. Britton A, McKee M, Black N, et al. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 1998;2:1-124
50. McKee M, Britton A, Black N, et al. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999;319:312-15